DCISionRT® by PreludeDx™ identiﬁes DCIS breast cancer patients at increased risk for breast cancer speciﬁc death (PRNewswire)
"Prelude Corporation (PreludeDx™)…presented data at the Miami Breast Cancer Conference (MBCC) 2021 Annual Meeting examining the association of DCISionRT® test results with breast cancer mortality (BCM) in patients diagnosed with ductal carcinoma in situ (DCIS). Study results demonstrated patients with higher DCISionRT scores had an increased risk of BCM... The primary endpoint of the study was to identify the association of DCISionRT test results with breast cancer mortality. DCISionRT Decision Score (DS) results were available for 157 of the 414 women. Primary DCIS was treated with breast conserving surgery (BCS) alone, BCS plus radiotherapy or mastectomy in 34%, 29% and 37% of the cases, respectively. Results revealed patients with increasing continuous DS had increasing BCM (OR=10, p=0.004), and patients with high categorical DS (>6) were at greater risk of BCM (OR=19, p=0.007)."